RE:RE:Science discussion - for TLT geeks only
Great points. Thanks for engaging in this as I do feel it is a small head scratcher in the whole process.
I'm not doing a very good job of articulating when I say slow growing. I guess what I'm thinking about his how some research into GBM, for example. found that the cancer was more heterogenous than just one mutated cell line. For some GBM there are a whole variety of EGFR mutations in the same mass.
I was just speculating that since TLD-1433 is so highly selective to the achilles heel, that selectivity may be great for the most problematic bladder cancer mass but may not always take care of all the cancer. Just thinking of one way for a cancer to persist on cytology but not get big enough to visualize very easily.
If TLT was great with sharing details, this kind of discussion would not be needed. They do keep some things a big vague so that is why I speculate.
I do think that avidity for thirsty cancer cells is a great ability for a drug to have. Exciting.
On another note, one thing I find exciting about Rutherrin for GBM and NSLC is that it is a new avenue that is not laser dependent. For the NIMBC protocol, each urology centre will have to buy a laser and then also buy the drug. For non-laser, xray based approach, TLT are just making and selling the drug. Simpler in a way. Less lucrative I guess as don't get the laser sales' income. But if you are collaborating around the world, selling a non-biologic drug to centres that already have xray ability should be a nicer launch than also having to train up on lasers. Just a random thought I had about the new indications in the future.
IMO
Happy New Year to all!